References
- Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment. Pharmacol. Ther.17, 643–650 (2003).
- Kang JY. Systematic review: the influence of geography and ethnicity in irritable bowel syndrome. Aliment. Pharmacol. Ther.21, 663–676 (2005).
- Gwee KA. Irritable bowel syndrome in developing countries – a disorder of civilization or colonization? Neurogastroenterol. Motil.17, 317–324 (2005).
- Simren M, Brazier J, Coremans G et al. Quality of life and illness costs in irritable bowel syndrome. Digestion69, 254–261 (2004).
- Quigley EMM, Bytzer P, Jones R, Mearin F. Irritable bowel syndrome: the burden and unmet needs in Europe. Dig. Liver Dis.38, 717–723 (2006).
- Quigley EMM, Bergmann J-F, Bytzer P et al. An evidence-based approach to the management of irritable bowel syndrome in Europe. Eur. J. Gastroenterol. Hepatol.19(Suppl. 1), S1–S37 (2007).
- Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology130, 1480–1491 (2006).
- Brandt LJ, Bjorkman D, Fennerty MB et al. Systematic review on the management of irritable bowel syndrome in North America. Am. J. Gastroenterol.97(Suppl. II), S7–S26 (2002).
- Mayer EA. Clinical practice. Irritable bowel syndrome. N. Engl. J. Med.358, 1692–1699 (2008).
- Tillisch K, Wang Z, Kilpatrick L, Holschneider DP, Mayer EA. Studying the brain–gut axis with pharmacological imaging. Ann. NY Acad. Sci.1144, 256–264 (2008).
- Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology124, 1662–1671 (2003).
- De Giorgio R, Barbara G. Is irritable bowel syndrome an inflammatory disorder? Curr. Gastroenterol. Rep.10, 385–390 (2008).
- Dinan TG, Quigley EMM, Ahmed SMM et al. Hypothalamic–pituitary–gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology130, 304–311 (2006).
- Quigley EMM. Disturbances of motility and visceral hypersensitivity in irritable bowel syndrome: biological markers or epiphenomenon. Gastroenterol. Clin. N. Am.34, 221–233 (2005).
- Quigley EMM. Bacteria: a new player in gastrointestinal motility disorders – infections, bacterial overgrowth and probiotics. Gastroenterol. Clin. N. Am.36, 735–748 (2007).
- Kassinen A, Krogius-Kurikka L, Mäkivuokko H et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology133, 24–33 (2007).
- Codling C, O’Mahony L, Shanahan F, Quigley EM, Marchesi JR. A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig. Dis. Sci. DOI: 10.1007/s10620-009-0934-x (2009) (Epub ahead of print).
- Dunlop SP, Jenkins D, Neal KR et al. Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment. Pharmacol. Ther.18, 77–84 (2003).
- Corinaldesi R, Stanghellini V, Cremon C et al. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof of concept study. Aliment. Pharmacol. Ther.30(3), 245–252 (2009).
- Pimentel M, Chow E, Lin H. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am. J. Gastroenterol.98, 412–419 (2003).
- Pimentel M, Park S, Mirocha J et al. The effect of a nonabsorbed antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann. Intern. Med.145, 557–563 (2006).
- Quigley EMM. A 51-year-old with irritable bowel syndrome: test or treat for bacterial overgrowth? Clin. Gastroenterol. Hepatol.5(10), 1140–1143 (2007).
- Vanner S. The small intestinal bacterial overgrowth irritable bowel syndrome hypothesis: implications for treatment. Gut57, 1315–1321 (2008).
- Ford AC, Spiegel BM, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. DOI: 10.1016/j.cgh.2009.06.031 (2009) (Epub ahead of print).
- Lembo A, Zakko SF, Ferreira NL et al. Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response. Gastroenterology134, A545 (2008).
- Nikfar S, Rahimi R, Rahimi F, Derakhshani S, Abdollahi M. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis. Colon Rectum51, 1775–1780 (2008).
- McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J. Gastroenterol.14, 2650–2661 (2008).
- Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol.9(1), 15 (2009).
- Moayyedi P, Ford AC, Talley NJ et al. The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut DOI: gut.2008.167270v1 (2008) (Epub ahead of print).
- Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am. J. Gastroenterol.104(4), 1033–1049 (2009).
- Kajander K, Krogius-Kurikka L, Rinttila T et al. Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome. Aliment. Pharmacol. Ther.26, 463–473 (2007).
- Kajander K, Myllyluoma E, Rajilić-Stojanović M et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment. Pharmacol. Ther.27, 48–57 (2008).
- O’Mahony L, McCarthy J, Kelly P et al. A randomized, placebo-controlled, double-blind comparison of the probiotic bacteria lactobacillus and bifidobacterium in irritable bowel syndrome (IBS): symptom responses and relationship to cytokine profiles. Gastroenterology128, 541–551 (2005).
- Agrawal A, Houghton LA, Morris J et al. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173–010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment. Pharmacol. Ther.29(1), 104–114 (2008).
- Roberfroid M. Prebiotics: the concept revisited. J. Nutr.137(3 Suppl. 2), S830–S837 (2007).
- Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut45(Suppl. 2), II43–II47 (1999).
- Depeint F, Tzprtzis G, Vulevic J, L’anson K, Gibson GR. Prebiotic evaluation of a novel galactooligosaccharide mixture produced by the enzymatic activity of Bifidobacterium bifidum NCIMB 44171, in healthy humans: a randomized, double-blind, crossover, placebo-controlled intervention study. Am. J. Clin. Nutr.87, 785–791 (2008).
- Vos AP, M’Rabert L, Stahl B, Boehm G, Garssen J. Immunomodulatory effects and potential working mechanisms of orally applied nondigestible carbohydrates. Crit. Rev. Immunol.27, 97–140 (2007).
- Biarti B, Matterelli P. The family Bifidobacteria. In: The Prokaryotes. Dworkin M, Fallow S, Rosenberg E, Schieifer KH, Stackebrandt E (Eds). Springer, NY, USA, 1–70 (2001).
- Whorwell PJ, Altringer L, Morel J et al. Efficacy of an encapsulated probiotic Bifidobacterium Infantis 35624 in women with irritable bowel syndrome. Am. J. Gastroenterol.101, 1581–1590 (2006).
- Guyonnet D, Chassany O, Ducrotte P et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment. Pharmacol. Ther.26, 475–486 (2007).
- Kim HJ, Camilleri M, McKenzie S et al. A randomized controlled trail of a probiotic, VSL#3 on gut transit and symptoms in diarrhoea-predominant IBS. Aliment. Pharmacol. Ther.17, 895–904 (2003).
- Kim HJ,Vazquez Roque MI, Camilleri M et al. A randomised controlled trial of probiotic combination VSL#3 and placebo in IBS with bloating: Neurogastroenterol. Motil.17, 687–696 (2005).
- Brandt LJ, Chey WD, Foxx-Orenstein AE et al. The American College of Gastroenterology Task force on IBS. An evidence-based position statement on the management of irritable bowel syndrome. Am. J. Gastroenterol.104(Suppl. 1), S1–S35 (2009).
- Ford AC, Talley NJ, Spiegel BM et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. Br. Med. J.337, A2313 (2008).
- Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut58, 367–378 (2009).
- Pasricha PJ. Desperately seeking serotonin. A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders. Gastroenterology132, 2287–2290 (2007).
- Hamilton-Miller JMT. Probiotics in the management of irritable bowel syndrome: a review of clinical trials. Microb. Ecol. Health Dis.13, 212–216 (2001).
- Quigley EM, Flourie B. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol. Motil.19, 166–172 (2007).
- Sen S, Mulan MM, Parker TJ et al. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig. Dis. Sci.47, 2615–2620 (2002).
- Barrett JS, Canale KE, Gearry RB, Irving PM, Gibson PR. Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome. World J. Gastroenterol.14, 5020–5024 (2008).
- Zeng J, Li YQ, Zuo XL, Zhen YB, Yang J, Liu CH. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther.28, 994–1002 (2008).
- Bueno L, de Ponti F, Fried M et al. Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity. Neurogastroenterol. Motil.19(1 Suppl.), 89–119 (2007).
- Rousseaux C, Thuru X, Gelot A et al.Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat. Med.13, 35–37 (2007).
- Silk DBA, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the effects of a trans-glucooligosaccharide on faecal microbiota and symptoms in irritable bowel syndrome. Aliment. Pharmacol. Ther.29, 508–518 (2009).
- Andriulli A, Neri M, Loguercio C et al. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized study. J. Clin. Gastroenterol.42(Suppl. 3 Pt 2), S218–S223 (2008).
- Colecchia A, Vestito A, La Rocca A, Pasqui F, Nikiforaki A, Festi D; Symbiotic Study Group. Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant. Results of an open, uncontrolled multicenter study. Minerva Gastroenterol. Dietol.52, 349–358 (2006).
- Tsuchiya J, Barreto R, Okura R et al. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin. J. Dig. Dis.5, 169–174 (2004).
- Dughera L, Elia C, Navino M, Cisarò F; ARMONIA Study Group. Effects of symbiotic preparations on constipated irritable bowel syndrome symptoms. Acta Biomed.78, 111–116 (2007).
- Bouhnik Y, Neut C, Raskine L et al. Prospective, randomized, parallel-group trial to evaluate the effects of lactulose and polyethylene glycol-4000 on colonic flora in chronic idiopathic constipation. Aliment. Pharmacol. Ther.19, 889–899 (2004).
- Dunne C, Murphy L, Flynn S et al. Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie Van Leeuwenhoek76, 279–292 (1999).